Bicyclic Heterocyclic Compounds for Multi-Target Huntington's Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no current small molecule therapies targeting the underlying cause of Huntington's disease, leaving a high unmet need for medications that can treat or ameliorate the condition.
Innovation Solution
Development of substituted bicyclic heterocyclic and substituted bicyclic heteroaryl compounds, such as those of Formula (I), which can be administered to subjects to treat or ameliorate Huntington's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no small molecule therapies are developed, then the unmet need for Huntington's disease treatment remains high, but developing new compounds requires significant research investment and time
Solution Approach 1:
The patent performs preliminary action by conducting extensive in silico screenings and in vitro validations before clinical development. The compounds were pre-screened against multiple HD-related targets (mutant huntingtin, polyQ aggregates, mTOR, PI3K/Akt pathways) and pre-validated for neuroprotective effects in cellular models, reducing the time and risk associated with later-stage development
Solution Approach 2:
The patent applies parameter changes by optimizing compound structures to achieve specific pharmacokinetic and pharmacodynamic properties. The bicyclic heterocyclic compounds were designed with specific molecular weights, lipophilicity, and binding affinities to cross the blood-brain barrier and target multiple HD-related pathways simultaneously, accelerating development through rational design
2Adaptability or versatility
If multiple therapeutic targets are pursued simultaneously, then comprehensive coverage of Huntington's disease mechanisms is achieved, but compound complexity and development difficulty increase
Solution Approach 1:
The patent applies universality by designing bicyclic heterocyclic compounds that can simultaneously target multiple Huntington's disease mechanisms including mutant huntingtin aggregation, polyQ repeat toxicity, mTOR hyperactivation, and PI3K/Akt pathway dysregulation. This multi-functional approach allows a single compound to address diverse pathological features without requiring separate therapies for each target
Solution Approach 2:
The patent uses composite materials principles by combining different heterocyclic building blocks (pyrimidine, pyridine, triazine rings) with various substituents to create compounds with multiple pharmacophores. This composite molecular structure enables simultaneous interaction with multiple biological targets while maintaining a unified compound identity that can be synthesized and standardized
Data Source
AI summary
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.